BIOGEN INC
BIIBNASDAQTrading Snapshot
- Day Range
- โ
- 52-Week Range
- $160.36 โ $261.00
- Volume (shares)
- โ
- Avg Volume (shares)
- โ
- Shares Outstanding
- 147.8M
- Next Earnings
- 2027-02-05
Fundamentals Snapshot
- Annual Revenue
- $9.81B
- Last Q Revenue
- $2.80B
- P/E Ratio
- 106.9
- P/S Ratio
- 3.6x
- EPS (TTM)
- $2.34
- Dividend Yield
- โ
- Dilution (1yr)
- +0.4%
BIOGEN INC
BIIBAbout BIOGEN INC
Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA targets non-Hodgkin's lymphoma and CLL, and GAZYVA is utilized for CLL and follicular lymphoma. OCREVUS addresses both relapsing and primary progressive forms of MS, complementing the company's broader efforts in anti-CD20 therapies. The company maintains a robust research and development pipeline, featuring numerous investigational therapies. These candidates are designed to tackle a wide spectrum of conditions, including multiple sclerosis and neuroimmunological disorders (e.g., BIIB135, BIIB061, BIIB091, BIIB107), Alzheimer's disease and other forms of dementia (e.g., Aducanumab, Lecanemab, BIIB076, BIIB080), neuromuscular disorders (e.g., BIIB067, BIIB078, BIIB105, BIIB100, BIIB110), Parkinson's disease and related movement disorders (e.g., BIIB124, BIIB094, BIIB118, BIIB101, BIIB122), neuropsychiatric conditions (e.g., BIIB125, BIIB104), immunology-related illnesses (e.g., Dapirolizumab pegol, BIIB059), acute neurological events (e.g., BIIB093, BIIB131), and neuropathic pain (e.g., BIIB074). Additionally, several biosimilar candidates, such as BYOOVIZ, BIIB800, and SB15, are progressing through various developmental stages. Biogen actively engages in strategic collaborations and licensing arrangements with various partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Established in 1978, Biogen Inc. maintains its corporate headquarters in Cambridge, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1โ5โ and equally weighted (20%), averaged to a 0โ100 score:๐ Quality โ gross margin๐ Growth โ revenue YoYโ๏ธ Valuation โ P/S ratioโก Momentum โ 30-day price change๐ง Dilution โ 1-yr share issuance (buybacks score higher)Latest News & Updates

Biogen: Why I'm Still Bullish Despite Market Turmoil
Biogen Inc. shares remain in an uptrend despite broader market pressure from the selloff in AI-related stocks. Its "star," called Leqembi, generated $202 million in Q3 global in-market sales, up 9.8% quarter-over-quarter

Biogen: M&A Growth And Alzheimer's Progress Are Now Priced In (Rating Downgrade)
Biogen Inc. moves from Buy to Hold: after a 20% gain, its valuation reasonably reflects growth and marginally positive Alzheimer's developments. BIIB trades above my July $223.70 DCF estimate; raising assumed growth from

Clarity AD CSF Substudy Findings on Lecanemab Treatment and ฮฑ-Synuclein Co-Pathology Presented at CTAD 2026
Lecanemab showed favorable results on clinical assessment scores at 18 months, including among individuals with early Alzheimer's disease (AD) who were ฮฑ-synuclein positive, a subgroup associated with higher amyloid burd

Biogen Prepares Joint Lupus Trial Results as It Targets First Revenue Growth Since 2019
Biogen (NASDAQ: BIIB) expects to announce results from two systemic lupus erythematosus trials together in a press release, as the company prepares for a series of pipeline readouts and seeks to return to revenue growth,

Biogen Inc. $BIIB Shares Bought by Bogart Wealth LLC
Bogart Wealth LLC increased its position in shares of Biogen Inc. (NASDAQ: BIIB) by 1,367.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. T

New Three-Year Real-World LEQEMBIยฎ Data Presented at CTAD 2026
Largest analysis of LEQEMBI LEADER study reported to date includes findings on amyloid clearance in routine clinical practice, delayed progression to moderate or severe AD, expanded subcutaneous maintenance experience, a